L&G Pharma Breakthrough UCITS ETF (BIGT)
Category Sector Equity Biotechnology
This ETF can be held in an Investment ISA, SIPP and Investment Account
Sell
1,081.80p
Buy
1,085.00p
21.30p (+2.01%)
Prices updated at 09 Oct 2026, 15:20 BST
| Prices minimum 15 mins delay
Prices in GBX
Investment objective
The investment objective of the Fund is to provide exposure to bio-technology companies that are actively engaged in the research, development and/or manufacturing of orphan drugs. In order to achieve this investment objective, the Fund will seek to track the performance of the Solactive Pharma Breakthrough Value Index Net Total Return (the “Index”). It will do so by investing primarily in a portfolio of equity securities that, as far as possible and practicable, consists of the component securities of the Index in similar proportions to their weightings in the Index and may have exposure to or invest directly up to 20% of its Net Asset Value in shares issued by the same body, which limit may be raised to 35% for a single issuer in exceptional market conditions, including (but not limited to) circumstances in which such issuer occupies a dominant market position.
Important notice: This product is based overseas and is not subject to UK sustainable investment labelling and disclosure requirements. Please refer to the FCA website which details further information in relation to sustainability disclosure requirements for retail clients.
Important documents: Please ensure that you have read the Key Information Document/Technical Guide or Product Summary document
, Pre-sale Illustrations document & Doing Business with Fidelity document (incorporating the Fidelity Client Terms) and the fund information documents. These can be found within the Charges & documents section.
- Key stats
- Price
- Performance
- Charges & documents
- Dividends
- Portfolio
- Risk profile
- Management
Portfolio as of 08/10/2026
Asset allocation
Show long & short position
Geographical breakdown
Continent or country allocation (%)
Market classification (%)
Stock style
Small core
19.33%
% Weight
Value
Core
Growth
Large
5
13
0
Medium
7
15
9
Small
12
19
19
Valuation
L&G Pharma Breakthrough UCITS ETF
Sector Equity Biotechnology
14.61
2.78
2.19
8.00
Growth rate
L&G Pharma Breakthrough UCITS ETF
Sector Equity Biotechnology
4.61%
0.64%
25.81%
Top 10 holdings
1
Xeris Biopharma Holdings Inc
Sector
Drug Manufacturers—Specialty & Generic
Country
United States
% of assets
3.18343
2
United Therapeutics Corp
Sector
Drug Manufacturers—Specialty & Generic
Country
United States
% of assets
2.91815
3
Genmab AS
Sector
Biotechnology
Country
Denmark
% of assets
2.79722
4
Ligand Pharmaceuticals Inc
Sector
Biotechnology
Country
United States
% of assets
2.75323
5
LG Chem Ltd
Sector
Chemicals
Country
South Korea
% of assets
2.73294
6
Rigel Pharmaceuticals Inc
Sector
Biotechnology
Country
United States
% of assets
2.66745
7
Halozyme Therapeutics Inc
Sector
Biotechnology
Country
United States
% of assets
2.66324
8
Basilea Pharmaceutica Ltd Registered Shares
Sector
Biotechnology
Country
Switzerland
% of assets
2.65674
9
Biogen Inc
Sector
Drug Manufacturers—General
Country
United States
% of assets
2.63563
10
Recordati SpA Az nom Post raggruppamento
Sector
Drug Manufacturers—General
Country
Italy
% of assets
2.62572
Assets in top 10 holdings %
27.63%
Total no. of equity holdings
41.00
Total no. of bond holdings
-
Stock sectors
L&G Pharma Breakthrough UCITS ETF
Sector Equity Biotechnology
2.74%
Basic materials
Con cyclical
Financial svs
Real estate
0.00%
Comm services
Energy
Industrials
Technology
97.26%
Con defensive
Healthcare
Utilities
